Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03752840 · ClinicalTrials.gov registry record · NA

Village-Integrated Eye Worker Trial II

A NA study of Glaucoma and Age-related Macular Degeneration, sponsored by University of California, San Francisco.

Recruiting
Registry status
NA
Development phase
60,200
Enrollment target
1
Study location

NCT03752840 is a NA study of Glaucoma and Age-related Macular Degeneration that is actively recruiting participants, run by University of California, San Francisco. The registered enrollment target is 60,200 participants, above the 256-participant average among 92 other Glaucoma trials with a reported enrollment target (23416% higher). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03752840, a NA study of Glaucoma and Age-related Macular Degeneration, is actively recruiting participants, sponsored by University of California, San Francisco.

RECRUITING
Registry status
NA
Development phase
60,200 participants
Enrollment target
1
Study location

Study Summary

The vast majority of blindness is avoidable. The World Health Organization (WHO) estimates that 80% of cases of visual impairment could be prevented or reversed with early diagnosis and treatment. The leading causes of visual impairment are cataract and refractive error, followed by glaucoma, age-related macular degeneration (AMD), and diabetic retinopathy (DR). Loss of vision from these conditions is not inevitable; however, identifying cases early and linking cases with appropriate care remain significant challenges. To address the global burden of avoidable blindness, eye care systems must determine optimal strategies for identifying people with or predisposed to visual impairment beyond opportunistic screening. Outreach programs can prevent blindness both by screening for asymptomatic disease like age-related macular degeneration (AMD), diabetic retinopathy (DR), and glaucoma and case detection of symptomatic disease like cataract and refractive error. Eye care systems have developed numerous approaches to these identification methods, including screening using telemedicine and case detection via cataract camps or health worker models, but no studies have been conducted on the comparative effectiveness or cost effectiveness of these various approaches. Technology promises to greatly improve access to sophisticated eye care. AMD, DR, and glaucoma can result in irreversible vision loss, and early diagnosis and effective treatment can prevent progression. Thus, mass screening programs may prevent progression and improve the vision of a population. However, mass screening for eye disease is currently not recommended. Although self-evident that early detection can prevent blindness for an individual, no randomized controlled trial has been able to demonstrate that screening improves visual acuity at the regional level. However, recent technological advances promise to dramatically change the equation by allowing non-medical personnel to use mobile, easy-to-use reti

Interventions

  • OTHER Visual acuity (presenting and pinhole)
  • OTHER Optical coherence tomography (OCT)
  • OTHER Intraocular pressure
  • OTHER Active linkage to care
  • OTHER Fundus Photography

Study Locations (1)

California

  • University of California, San Francisco - San Francisco

Trial Details

FieldValue
Enrollment Target 60,200 participants
Start Date 2019-04-21
Est. Completion 2029-08-31
Phase NA

What the Registry Record Tells You About NCT03752840

The ClinicalTrials.gov registry entry for NCT03752840 describes a study currently listed as recruiting, categorized as NA. The registered enrollment target is 60,200 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 256-participant average among 92 other Glaucoma trials with a reported enrollment target (23416% higher). The listed sponsor is University of California, San Francisco, which has 1,713 total studies on file at ClinicalTrials.gov.

The record links to 3 conditions, with Glaucoma appearing as the primary indexed condition, and to 5 interventions - of which Visual acuity (presenting and pinhole) is the first listed.

NCT03752840 reports 1 study location spanning 1 distinct geographic area - top geographies include California.

Frequently Asked Questions

What is clinical trial NCT03752840 about?

NCT03752840 is a clinical study titled "Village-Integrated Eye Worker Trial II". The vast majority of blindness is avoidable. The World Health Organization (WHO) estimates that 80% of cases of visual impairment could be prevented or reversed with early diagnosis and treatment. The leading causes of visual impairment are cataract and refractive error, followed by glaucoma, age-re...

What is the current status of trial NCT03752840?

This trial is currently recruiting. It is a NA study. The enrollment target is 60,200 participants. The study started on 2019-04-21. Estimated completion is 2029-08-31.

What conditions does trial NCT03752840 study?

This clinical trial studies the following conditions: Glaucoma, Age-related Macular Degeneration, Diabetic Retinopathy.

What interventions are being tested in trial NCT03752840?

The interventions under investigation include: Visual acuity (presenting and pinhole) (OTHER), Optical coherence tomography (OCT) (OTHER), Intraocular pressure (OTHER), Active linkage to care (OTHER), Fundus Photography (OTHER).

Who is sponsoring clinical trial NCT03752840?

This trial is sponsored by University of California, San Francisco, which has 1,713 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT03752840 being conducted?

This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Glaucoma

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.